137 related articles for article (PubMed ID: 19415885)
1. Temsirolimus: new drug. Metastatic kidney cancer: more assessment needed.
Prescrire Int; 2008 Dec; 17(98):223-5. PubMed ID: 19415885
[TBL] [Abstract][Full Text] [Related]
2. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
[TBL] [Abstract][Full Text] [Related]
4. Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.
Afshar M; Pascoe J; Whitmarsh S; James N; Porfiri E
Drug Des Devel Ther; 2015; 9():13-9. PubMed ID: 25552898
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.
Hudes GR; Berkenblit A; Feingold J; Atkins MB; Rini BI; Dutcher J
Semin Oncol; 2009 Dec; 36 Suppl 3():S26-36. PubMed ID: 19963097
[TBL] [Abstract][Full Text] [Related]
6. FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.
Kwitkowski VE; Prowell TM; Ibrahim A; Farrell AT; Justice R; Mitchell SS; Sridhara R; Pazdur R
Oncologist; 2010; 15(4):428-35. PubMed ID: 20332142
[TBL] [Abstract][Full Text] [Related]
7. Temsirolimus in renal cell carcinoma.
Otto T; Eimer C; Gerullis H
Transplant Proc; 2008 Dec; 40(10 Suppl):S36-9. PubMed ID: 19100905
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
9. [ASCO 2006: temsirolimus increases survival].
Aktuelle Urol; 2006 Sep; 37(5 Suppl):12. PubMed ID: 23646393
[No Abstract] [Full Text] [Related]
10. Temsirolimus: in advanced renal cell carcinoma.
Simpson D; Curran MP
Drugs; 2008; 68(5):631-8. PubMed ID: 18370442
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma.
Hoyle M; Green C; Thompson-Coon J; Liu Z; Welch K; Moxham T; Stein K
Value Health; 2010; 13(1):61-8. PubMed ID: 19804430
[TBL] [Abstract][Full Text] [Related]
12. Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.
Malizzia LJ; Hsu A
Clin J Oncol Nurs; 2008 Aug; 12(4):639-46. PubMed ID: 18676330
[TBL] [Abstract][Full Text] [Related]
13. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
[TBL] [Abstract][Full Text] [Related]
14. Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.
Figlin RA; de Souza P; McDermott D; Dutcher JP; Berkenblit A; Thiele A; Krygowski M; Strahs A; Feingold J; Boni J; Hudes G
Cancer; 2009 Aug; 115(16):3651-60. PubMed ID: 19526589
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
16. Safety profile of temsirolimus in patients with metastatic renal cell carcinoma.
Levakov I; Vojinov S; Marusic G; Popov M; Levakov O; Popov M; Jeremic D
J BUON; 2016; 21(6):1442-1448. PubMed ID: 28039705
[TBL] [Abstract][Full Text] [Related]
17. Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus.
Maroto JP; Hudes G; Dutcher JP; Logan TF; White CS; Krygowski M; Cincotta M; Shapiro M; Duran I; Berkenblit A
J Clin Oncol; 2011 May; 29(13):1750-6. PubMed ID: 21444868
[TBL] [Abstract][Full Text] [Related]
18. Sunitinib: new drug. For some gastrointestinal stromal tumours.
Prescrire Int; 2007 Aug; 16(90):138-41. PubMed ID: 17724833
[TBL] [Abstract][Full Text] [Related]
19. [Adverse events associated with temsirolimus for patients with metastatic renal cell carcinoma].
Miyake H; Fujisawa M
Hinyokika Kiyo; 2012 Nov; 58(11):651-4. PubMed ID: 23254795
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H
Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
